New Insight into the Framing of Antibody-Mediated Rejection in Lung Transplant

Wednesday, 17 November, 2021, 1:00 – 2:00 p.m. EDT

This webinar will provide an update on antibody-mediated rejection (AMR) following lung transplantation, an important cause of graft dysfunction and loss. At this stage, it is critical that lung transplant clinicians, pathologists and immunologists have a strong understanding of the criteria for the timely diagnosis and assessment of AMR and of the approaches to use for the optimal management of such a condition. Following discussion of the index case, brief overviews will be provided by international experts who will present the latest developments in this field, with particular focus on new AMR statement that is soon-to-come.

Scientific Program

Antoine Roux, MD, PhD

Welcome and Introductions
Antoine Roux, MD, PhD, Foch Hospital, Suresnes, France

CASE PRESENTATION: a Highly Sensitized Patient with Donor-Specific Antibodies Prior to Lung Transplantation
Emanuele Cozzi, MD, PhD, University of Padova, Padova, Italy
This case presentation will describe a highly sensitized patient with DSA who underwent lung transplantation and developed antibody-mediated rejection.

Challenges of the Sensitized Candidate
Adriana Zeevi, MD, University of Pittsburgh, Pittsburgh, PA, USA
This talk will start with the current knowledge on the role of pre-existing and de novo anti-HLA and non-HLA antibodies in lung transplantation, highlight pros/cons of lung transplantation in hyperimmunized recipients, and spotlight new guidelines from an immunological standpoint.

The Contribution of the Pathologist: Histology is Not Enough
Fiorella Calabrese, MD, University of Padova, Padova, Italy
Anja Roden, MD, Mayo Clinic, Rochester, MN, USA
These talks will focus on the description of the most relevant histopathological lesions suggestive of lung antibody-mediated rejection and the important contribution of other tools now available in the armamentarium of Pathology labs. The speakers will also discuss morphological aspects that will be included in the new AMR statement.

Diagnosis and Clinical Management of Antibody-Mediated Rejection in Lung Transplanted Patients
Detection and Diagnosis of AMR: Deborah Levine, MD, UT Health, San Antonio, TX, USA
Management of AMR: Ramsey Hachem, MD, Washington Univ SoM, St Louis, MO, USA
These expert clinicians will discuss the ideal clinical follow up of transplant recipients and the critical signs that should raise attention of care providers. Both speakers will highlight some aspects about the diagnosis and therapeutic approaches that will be reported in the new statement.

Live Q&A Segment with All Speakers
Led by Moderator

Closing Remarks
Antoine Roux, MD, PhD, Foch Hospital, Suresnes, France

ISHLT Announcements
Greg Schultz, ISHLT CEO

Continuing Education Information

There will be no continuing education available for this webinar.